The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Scoring treatment response in patients with relapsing multiple sclerosis
Abstract
Background: We employed clinical and magnetic resonance imaging (MRI) measures in combination, to assess patient responses to interferon in multiple sclerosis. Objective: To optimize and validate a scoring system able to discriminate responses to interferon treatment in patients with relapsing–remitting multiple sclerosis (RRMS). Methods: Our analysis included two large, independent datasets of RRMS patients who were treated with interferons that included 4-year follow-up data. The first dataset (“training set”) comprised of 373 RRMS patients from a randomized clinical trial of subcutaneous interferon beta-1a. The second (“validation set”) included an observational cohort of 222 RRMS patients treated with different interferons. The new scoring system, a modified version of that previously proposed by Rio et al., was first tested on the training set, then validated using the validation set. The association between disability progression and risk group, as defined by the score, was evaluated by Kaplan Meier survival curves and Cox regression, and quantified by hazard ratios (HRs). Results: The score (0–3) was based on the number of new T2 lesions (>5) and clinical relapses (0,1 or 2) during the first year of therapy. The risk of disability progression increased with higher scores. In the validation set, patients with score of 0 showed a 3-year progression probability of 24%, while those with a score of 1 increased to 33% (HR = 1.56; p = 0.13), and those with score greater than or equal to 2 increased to 65% (HR = 4.60; p < 0.001). Conclusions: We report development of a simple, quantitative and complementary tool for predicting responses in interferon-treated patients that could help clinicians make treatment decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
SERIAL GADOLINIUM ENHANCED MAGNETIC RESONANCE IMAGING IN MULTIPLE SCLEROSIS
MILLER, D. H., RUDGE, P., JOHNSON, G., KENDALL, B. E., MACMANUS, D. G., MOSELEY, I. F., BARNES, D., & MCDONALD, W. I. (1988) · Brain · doi:10.1093/brain/111.4.927 · Cited by 407
Noseworthy, J. H., Vandervoort, M. K., Wong, C. J., & Ebers, G. C. (1990) · Neurology · doi:10.1212/wnl.40.6.971 · Cited by 328
Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients
Río, J., Nos, C., Tintoré, M., Téllez, N., Galán, I., Pelayo, R., Comabella, M., & Montalban, X. (2006) · Annals of Neurology · doi:10.1002/ana.20740 · Cited by 327
Self-citationMeasures in the first year of therapy predict the response to interferon β in MS
Río, J., Castilló, J., Rovira, A., Tintoré, M., Sastre-Garriga, J., Horga, A., Nos, C., Comabella, M., Aymerich, X., & Montalbán, X. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458509104591 · Cited by 244
Self-citationDefining interferon β response status in multiple sclerosis patients
Rudick, R. A., Lee, J., Simon, J., Ransohoff, R. M., & Fisher, E. (2004) · Annals of Neurology · doi:10.1002/ana.20224 · Cited by 217
Goodkin, D. E., Cookfair, D., Wende, K., Bourdette, D., Pullicino, P., Scherokman, B., & Whitham, R. (1992) · Neurology · doi:10.1212/wnl.42.4.859 · Cited by 212
One‐year MRI scan predicts clinical response to interferon beta in multiple sclerosis
Prosperini, L., Gallo, V., Petsas, N., Borriello, G., & Pozzilli, C. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02708.x · Cited by 128
Predictors of long–term clinical response to interferon beta therapy in relapsing multiple sclerosis
Tomassini, V., Paolillo, A., Russo, P., Giugni, E., Prosperini, L., Gasperini, C., Antonelli, G., Bastianello, S., & Pozzilli, C. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0979-5 · Cited by 123
Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis
Sormani, M. P., Li, D. K., Bruzzi, P., Stubinski, B., Cornelisse, P., Rocak, S., & Stefano, N. D. (2011) · Neurology · doi:10.1212/wnl.0b013e31823648b9 · Cited by 114
Self-citation
Cited by
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Montalban, X., Gold, R., Thompson, A. J., Otero-Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comi, G., Derfuss, T., Fazekas, F., et al. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458517751049 · Cited by 712
Self-citationMultiple sclerosis: clinical aspects
Oh, J., Vidal-Jordana, A., & Montalban, X. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000622 · Cited by 620
on behalf of the MAGNIMS study group (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.157 · Cited by 473
Brain health: time matters in multiple sclerosis
Giovannoni, G., Butzkueven, H., Dhib-Jalbut, S., Hobart, J., Kobelt, G., Pepper, G., Sormani, M. P., Thalheim, C., Traboulsee, A., & Vollmer, T. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.07.003 · Cited by 458
Self-citationHarding, K., Williams, O., Willis, M., Hrastelj, J., Rimmer, A., Joseph, F., Tomassini, V., Wardle, M., Pickersgill, T., Robertson, N., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4905 · Cited by 366
Metadata
- Authors
- Sormani, M., Rio, J., Tintorè, M., Signori, A., Li, D., Cornelisse, P., Stubinski, B., Stromillo, M., Montalban, X., & De Stefano, N.
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2012-09-25
- Volume
- 19
- Issue
- 5
- Pages
- 605-612
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W1965997336
- Cited by
- 262
- References
- 13
- FWCI
- 12.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Scoring treatment response in patients with relapsing multiple sclerosis. https://app.cochat.ai/papers/10.1177/1352458512460605
- The paper
- Sormani, M., Rio, J., Tintorè, M., Signori, A., Li, D., Cornelisse, P., Stubinski, B., Stromillo, M., Montalban, X., & De Stefano, N. (2013). Scoring treatment response in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458512460605
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.